לבטיראצטם דקסל 250 ישראל - עברית - Ministry of Health

לבטיראצטם דקסל 250

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 250 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

לבטיראצטם דקסל 500 ישראל - עברית - Ministry of Health

לבטיראצטם דקסל 500

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 500 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

לבטיראצטם דקסל 750 ישראל - עברית - Ministry of Health

לבטיראצטם דקסל 750

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 750 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

לבטיראצטם דקסל 1000 ישראל - עברית - Ministry of Health

לבטיראצטם דקסל 1000

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 1000 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

לוותרים 250 ישראל - עברית - Ministry of Health

לוותרים 250

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 250 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

לוותרים 500 ישראל - עברית - Ministry of Health

לוותרים 500

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 500 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

לוותרים 1000 ישראל - עברית - Ministry of Health

לוותרים 1000

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 1000 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

קפרה 250 מג ישראל - עברית - Ministry of Health

קפרה 250 מג

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 250 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

קפרה 500 מג ישראל - עברית - Ministry of Health

קפרה 500 מג

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 500 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

קפרה 1000 מג ישראל - עברית - Ministry of Health

קפרה 1000 מג

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 1000 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.